High expression of CD7 on CD34+ cells is not linked to deletion of derivative chromosome 9 or lack of dendritic cells in chronic myeloid leukaemia

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 68, Issue 2, 2008, Pages 93-98

  Floisand Y ^a   Normann, A P ^a   Heim, S ^a,b   Lund Johansen, F ^a   Tjonnfjord G E ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

CD34+CD7+ cells; Chronic myeloid leukaemia (CML); Del der(9); Myeloid dendritic cells; Plasmacytoid dendritic cells; Prognosis

Indexed keywords

CD34 ANTIGEN; CD7 ANTIGEN;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CHROMOSOME 9; CHROMOSOME DELETION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; MALE; NORWAY; PLASMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; AGED; ANTIGENS, CD34; ANTIGENS, CD7; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 9; DENDRITIC CELLS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED;

EID: 41649116237     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.1080/00365510701558477     Document Type: Article

References (25)

1. Groffen J, Heisterkamp N. The chimeric BCR-ABL gene. Baillières Clin Haematol 1997;10:187-201.
2. Goldman JM. Treatment of chronic myeloid leukaemia: some topical questions. Baillières Clin Haematol 1997;10:405-21.
3. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984;63:789-99.
4. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 1998;90:850-8.
5. Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood 1994;84:4064-77.
6. Deininger MW. Management of early stage disease. Hematology/the Education Program of the American Society of Hematology. Am Soc Hematol, 2005:174-82.
7. Normann AP, Egeland T, Madshus IH, Heim S, Tjonnfjord GE. CD7 expression by CD34+ cells in CML patients, of prognostic significance? Eur J Haematol 2003;71:266-75.
8. Yong AS, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML. Blood 2006;107:205-12.
9. Martin-Henao GA, Quiroga R, Sureda A, Garcia J. CD7 expression on CD34+ cells from chronic myeloid leukaemia in chronic phase. Am J Hematol 1999;61:178-86.
10. Steen R, Tjonnfjord GE, Egeland T. Comparison of the phenotype and clonogenicity of normal CD34+ cells from umbilical cord blood, granulocyte colony-stimulating factor-mobilized peripheral blood, and adult human bone marrow. J Hematother 1994;3:253-62.
11. Tjonnfjord GE, Steen R, Evensen SA, Thorsby E, Egeland T. Characterization of CD34+ peripheral blood cells from healthy adults mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1994;84:2795-801.
12. Mohty M, Isnardon D, Vey N, Briere F, Blaise D, Olive D, et al. Low blood dendritic cells in chronic myeloid leukaemia patients correlates with loss of CD34+/CD38-primitive haematopoietic progenitors. Br J Haematol 2002;119:115-18.
13. Boissel N, Rousselot P, Raffoux E, Cayuela JM, Maarek O, Charron D, et al. Defective blood dendritic cells in chronic myeloid leukemia correlate with high plasmatic VEGF and are not normalized by imatinib mesylate. Leukemia 2004;18:1656-61.
14. Sinclair PB, Nacheva EP, Leversha M, Telford N, Chang J, Reid A, et al. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 2000;95:738-43.
15. Huntly BJ, Reid AG, Bench AJ, Campbell LJ, Telford N, Shepherd P, et al. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 2001;98:1732-8.
16. Kolomietz E, Al-Maghrabi J, Brennan S, Karaskova J, Minkin S, Lipton J, et al. Primary chromosomal rearrangements of leukemia are frequently accompanied by extensive submicroscopic deletions and may lead to altered prognosis. Blood 2001;97:3581-8.
17. Cohen N, Rozenfeld-Granot G, Hardan I, Brok-Simoni F, Amariglio N, Rechavi G, et al. Subgroup of patients with Philadelphia-positive chronic myelogenous leukemia characterized by a deletion of 9q proximal to ABL gene: expression profiling, resistance to interferon therapy, and poor prognosis. Cancer Genet Cytogenet 2001;128:114-19.
18. Huntly BJ, Bench AJ, Delabesse E, Reid AG, Li J, Scott MA, et al. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 2002;99:4547-53.
19. Fourouclas N, Campbell PJ, Bench AJ, Swanton S, Baxter EJ, Huntly BJ, et al. Size matters: the prognostic implications of large and small deletions of the derivative 9 chromosome in chronic myeloid leukemia. Haematologica 2006;91:952-5.
20. Huntly BJ, Bench A, Green AR. Double jeopardy from a single translocation: deletions of the derivative chromosome 9 in chronic myeloid leukemia. Blood 2003;102:1160-8.
21. Mitelman F. An international system for human cytogenetics nomenclature. Basel: S. Karger; 1995.
22. Olweus J, BitMansour A, Warnke R, Thompson PA, Carballido J, Picker LJ, et al. Dendritic cell ontogeny: a human dendritic cell lineage of myeloid origin. Proc Natl Acad Sci USA 1997;94:12551-6.
23. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, et al. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487-93.
24. Allan NC, Richards SM, Shepherd PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet 1995;345:1392-7.
25. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284:1835-7.